Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Smart move by TLT management...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1099)
•••
Comment by CancerSlayeron Jul 11, 2024 8:26pm
210 Views
Post# 36129452

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Smart move by TLT management...

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Smart move by TLT management...
Mikee3003 wrote: Yes Infinity they do have an impressive list of patents however I will respectfully disagree that they can be monitized through a financial institution. What lenders need are tangible assets not intangible ones that currently have no revenue streams, rights etc.....hopefully one day those patents can be used as be used as collateral on debt financing but just not now. Further to my point TLT is having a rough time raising funds, do you really think that if they could just pitch their case to a financial institution they wouldn't have already done that? Cmon..........



It may be wise to patiently wait...I agree it would be difficult to get IP-based financing pre-BTD stage; however, post-BTD would bring this company one significant step closer to commercialization/revenue generation.  Such a step forward would certainly help open the eyes of an alternative lender or investment arm of a bank...imo.  This company's IP also uniquely differentiates itself from the rest of the market, which is eye candy to any potential lender who is looking for a unique value proposition....one lender in the North comes to mind in the name of BDC Capital, the investment division of Business Development Bank of Canada. They appear to understand the value of intangible assets & what potential these assets have for future market share.  I'd argue that such a non-dilutive financing post-BTD (if attainable) is not only a realistic path, but a preferable one.  

A promising small biotech's value builds exponentially (vs incrementally) the closer it gets to an FDA approval/commercialization.  And having non-dilutive funds to also advance/clinically validate other indications would simply create additional exponential value before that eventual partnership or buyout.  Exercising financial patience with reasonable dilution along the way may be the prudent play...if I dare say.  JMO...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities